Excessive Phlebotomy in Cardiac Surgical Care Leads to Anemia
|
By LabMedica International staff writers Posted on 01 Apr 2015 |

Image: Phlebotomy or venipuncture performed to obtain blood for laboratory tests (Photo courtesy of Sweet Water Health and Education).
Laboratory testing among patients undergoing cardiac surgery can lead to excessive bloodletting, which can increase the risk of developing hospital-acquired anemia and the need for blood transfusion.
Health care providers are seldom aware of the frequency and volume of phlebotomy for laboratory testing, bloodletting that often leads to nosocomial anemia. The frequency of laboratory testing in patients undergoing cardiac surgery, and the cumulative phlebotomy volume from time of initial surgical consultation to hospital discharge has been investigated.
Medical teams at the Cleveland Clinic (Cleveland, OH, USA) examined every laboratory test from 1,894 patients who underwent cardiac surgery from January to June 2012. The number and type of blood tests performed were recorded from the time patients met their surgeons until hospital discharge. The scientists then tallied up the total amount of blood taken from each patient. Phlebotomy volume was estimated separately for the intensive care unit (ICU), hospital floors, and cumulatively.
A total of 221,498 laboratory tests were performed, averaging 115 tests per patient. The most frequently performed tests were 88,068 blood gas analyses, 39,535 coagulation tests, 30,421 complete blood counts, and 29,374 metabolic panels. Phlebotomy volume differed between ICU and hospital floors, with median volumes of 332 mL and 118 mL, respectively. Cumulative median volume for the entire hospital stay was 454 mL. More complex procedures were associated with higher overall phlebotomy volume than isolated procedures. Foe combined coronary artery bypass grafting (CABG) and valve procedure, the median volume was 653 mL versus 448 mL for isolated CABG and 338 mL for isolated valve procedures.
Colleen G. Koch, MD, MS, MBA, the lead author of the study said, “We were astonished by the amount of blood taken from our patients for laboratory testing. Total phlebotomy volumes approached one to two units of red blood cells, which is roughly equivalent to one to two cans of carbonated beverage. Patients should feel empowered to ask their doctors whether a specific test is necessary, such as: What is the indication for the test? Will it change my care? And if so, do you need to do it every day? They should inquire whether smaller volume test tubes could be used for the tests that are deemed necessary. Every attempt should be made to conserve the patient's own blood, every drop of blood counts.” The study was published in the March 2015 issue of the journal the Annals of Thoracic Surgery.
Related Links:
Cleveland Clinic
Health care providers are seldom aware of the frequency and volume of phlebotomy for laboratory testing, bloodletting that often leads to nosocomial anemia. The frequency of laboratory testing in patients undergoing cardiac surgery, and the cumulative phlebotomy volume from time of initial surgical consultation to hospital discharge has been investigated.
Medical teams at the Cleveland Clinic (Cleveland, OH, USA) examined every laboratory test from 1,894 patients who underwent cardiac surgery from January to June 2012. The number and type of blood tests performed were recorded from the time patients met their surgeons until hospital discharge. The scientists then tallied up the total amount of blood taken from each patient. Phlebotomy volume was estimated separately for the intensive care unit (ICU), hospital floors, and cumulatively.
A total of 221,498 laboratory tests were performed, averaging 115 tests per patient. The most frequently performed tests were 88,068 blood gas analyses, 39,535 coagulation tests, 30,421 complete blood counts, and 29,374 metabolic panels. Phlebotomy volume differed between ICU and hospital floors, with median volumes of 332 mL and 118 mL, respectively. Cumulative median volume for the entire hospital stay was 454 mL. More complex procedures were associated with higher overall phlebotomy volume than isolated procedures. Foe combined coronary artery bypass grafting (CABG) and valve procedure, the median volume was 653 mL versus 448 mL for isolated CABG and 338 mL for isolated valve procedures.
Colleen G. Koch, MD, MS, MBA, the lead author of the study said, “We were astonished by the amount of blood taken from our patients for laboratory testing. Total phlebotomy volumes approached one to two units of red blood cells, which is roughly equivalent to one to two cans of carbonated beverage. Patients should feel empowered to ask their doctors whether a specific test is necessary, such as: What is the indication for the test? Will it change my care? And if so, do you need to do it every day? They should inquire whether smaller volume test tubes could be used for the tests that are deemed necessary. Every attempt should be made to conserve the patient's own blood, every drop of blood counts.” The study was published in the March 2015 issue of the journal the Annals of Thoracic Surgery.
Related Links:
Cleveland Clinic
Latest Clinical Chem. News
- At-Home Blood and Cognitive Tests Support Dementia Risk Stratification
- Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
- Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
- Blood Test Detects Testicular Cancer Missed by Standard Markers
- Routine Blood Tests Identify Biomarkers Linked to PTSD
- Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges
- Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk
- Label-Free Microfluidic Device Enriches Tumor Cells and Clusters from Pleural Effusions
- Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection
- Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
- Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
- Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
- AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
- Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
- Blood Metabolite Test Detects Early Cognitive Decline
- AI-Based Blood Test Diagnose Multiple Brain Disorders from Blood Sample
Channels
Clinical Chemistry
view channelAt-Home Blood and Cognitive Tests Support Dementia Risk Stratification
Dementia places a substantial burden on patients and health systems, and identifying individuals at elevated risk remains difficult at scale. In the UK, almost a million people are estimated to be living... Read more
Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
Dementia affects more than 57 million people worldwide and is projected to nearly double within two decades, straining health systems and families. While biomarkers now enable accurate identification of... Read moreMolecular Diagnostics
view channel
Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Patented Isothermal Amplification Chemistry Advances Decentralized Testing
Molecular diagnostics offer high sensitivity for pathogen detection but typically rely on thermal cycling and specialized instruments, limiting their use outside centralized laboratories.... Read more
Finger-Prick Blood Test Aids Early Tuberculosis Detection and Risk Stratification
Household contacts of people with tuberculosis face an estimated 2% risk of developing disease, yet most are asymptomatic at the time of screening. Early-stage cases are often missed because symptom checks... Read more
Urine Test Beats MRI in Identifying Prostate Cancer Upgrading During Active Surveillance
Active surveillance is common for men with low-risk prostate cancer, yet deciding when to repeat biopsy remains challenging. Prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI)... Read moreImmunology
view channel
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read moreMicrobiology
view channel
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read more
Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
Early detection of gastric cancer could be advanced by scalable screening strategies using minimally invasive sampling. Saliva collection is noninvasive and cost-effective, supporting wider adoption... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more








